Verastem Inc logo

VSTM - Verastem Inc Share Price

$2.2 0.0  0.5%

Last Trade - 22/01/21

Sector
Healthcare
Size
Small Cap
Market Cap £270.8m
Enterprise Value £187.8m
Revenue £66.7m
Position in Universe 3656th / 6625
Bullish
Bearish
Unlock VSTM Revenue
Momentum
Relative Strength (%)
1m -10.7%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -53.1%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 26.7 17.5 88.0 5.00
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020,Verastem Inc revenues increased from $13.8M to $88M. Netloss decreased 57% to $47.9M. Revenues reflect Productrevenue, net increase of 73% to $15.1M. Lower net lossreflects Selling, general and administrative decrease of28% to $55.7M (expense), Research and development decreaseof 6% to $31.2M (expense), Interest expense decrease of 5%to $14.4M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

VSTM Revenue Unlock VSTM Revenue

Net Income

VSTM Net Income Unlock VSTM Revenue

Normalised EPS

VSTM Normalised EPS Unlock VSTM Revenue

PE Ratio Range

VSTM PE Ratio Range Unlock VSTM Revenue

Dividend Yield Range

VSTM Dividend Yield Range Unlock VSTM Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
VSTM EPS Forecasts Unlock VSTM Revenue
Profile Summary

Verastem, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing medicines to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s marketed and developing products include defactinib and VS-6766. Defactinib is an oral small molecule inhibitor of FAK and PYK2 that is being evaluated as a potential combination therapy for various solid tumors. It is engaged in running clinical trials in cancers where there are limited treatment options, including leukemia, lymphoma, lung cancer, mesothelioma, ovarian cancer, head and neck cancer, colorectal cancer and pancreatic cancer. VS-6766 is an inhibitor of the RAF/MEK signaling pathway. VS-6766 blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated August 4, 2010
Public Since November 8, 2011
No. of Shareholders: 11
No. of Employees: 135
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 169,774,432
Free Float (0.0%)
Eligible for
ISAs
SIPPs
VSTM Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for VSTM
Upcoming Events for VSTM
Wednesday 19th May, 2021 Estimate
Verastem Inc Annual Shareholders Meeting
Frequently Asked Questions for Verastem Inc
What is the Verastem Inc share price?

As of 22/01/21, shares in Verastem Inc are trading at $2.2, giving the company a market capitalisation of £270.8m. This share price information is delayed by 15 minutes.

How has the Verastem Inc share price performed this year?

Shares in Verastem Inc are currently trading at $2.2 and the price has moved by 14.66% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Verastem Inc price has moved by -1.01% over the past year.

What are the analyst and broker recommendations for Verastem Inc?

Of the analysts with advisory recommendations for Verastem Inc, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Verastem Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Verastem Inc next release its financial results?

Verastem Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Verastem Inc dividend yield?

Verastem Inc does not currently pay a dividend.

Does Verastem Inc pay a dividend?

Verastem Inc does not currently pay a dividend.

When does Verastem Inc next pay dividends?

Verastem Inc does not currently pay a dividend.

How do I buy Verastem Inc shares?

To buy shares in Verastem Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Verastem Inc?

Shares in Verastem Inc are currently trading at $2.2, giving the company a market capitalisation of £270.8m.

Where are Verastem Inc shares listed? Where are Verastem Inc shares listed?

Here are the trading details for Verastem Inc:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: VSTM
What kind of share is Verastem Inc?

Based on an overall assessment of its quality, value and momentum, Verastem Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Verastem Inc share price forecast 2021?

Shares in Verastem Inc are currently priced at $2.2. At that level they are trading at 74.89% discount to the analyst consensus target price of 0.00.

Analysts covering Verastem Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.405 for the next financial year.

How can I tell whether the Verastem Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Verastem Inc. Over the past six months, the relative strength of its shares against the market has been 26.15%. At the current price of $2.2, shares in Verastem Inc are trading at 23.56% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Verastem Inc PE Ratio?

We were not able to find PE ratio data for Verastem Inc.

Who are the key directors of Verastem Inc?

Verastem Inc's management team is headed by:

Alison Lawton - IND
Michael Kauffman - LED
Daniel Paterson - PRE
Timothy Barberich - IND
Eric Rowinsky - IND
Brian Stuglik - CEO
Robert Gagnon - CFO
Gina Consylman - IND
Who are the major shareholders of Verastem Inc?

Here are the top five shareholders of Verastem Inc based on the size of their shareholding:

BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 6.54% (11.1m shares)
BVF Partners L.P. Hedge Fund
Percentage owned: 6.33% (10.7m shares)
Ridgeback Capital Management, L.P. Hedge Fund
Percentage owned: 5.93% (10.1m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 4.82% (8.19m shares)
RA Capital Management, LP Hedge Fund
Percentage owned: 4.75% (8.07m shares)
Similar to VSTM
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.